On March 28, 2024, Gilead Sciences announced that it has filed a definitive proxy statement with Securities and Exchange Commission stating that it has received a shareholder proposal from Bowyer Research, Inc. on behalf of David Bahnsen, Trustee of The Bahnsen Family Trust, requesting the Company to issue a public report prior to December 31, 2024, omitting confidential and privileged information and at a reasonable expense, detailing the known and reasonably foreseeable risks and costs to the Company caused by opposing or otherwise altering Company policy in response to enacted or proposed state policies regulating abortion, and detailing any strategies beyond litigation and legal compliance that the Company may deploy to minimize or mitigate these risks. In addition, the Company urged the shareholders to vote against the shareholder proposal at its annual general meeting of shareholders scheduled to be held on May 8, 2024.